Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Warfarin is very effective in preventing recurrent venous thromboembolism but is also associated with a substantial risk of bleeding. After three months of conventional warfarin therapy, a lower dose of anticoagulant medication may result in less bleeding and still prevent recurrent venous thromboembolism. METHODS: We conducted a randomized, double-blind study, in which 738 patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism were randomly assigned to continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 (conventional intensity) or a target INR of 1.5 to 1.9 (low intensity). Patients were followed for an average of 2.4 years. RESULTS: Of 369 patients assigned to low-intensity therapy, 16 had recurrent venous thromboembolism (1.9 per 100 person-years), as compared with 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio, 2.8; 95 percent confidence interval, 1.1 to 7.0). A major bleeding episode occurred in nine patients assigned to low-intensity therapy (1.1 events per 100 person-years) and eight patients assigned to conventional-intensity therapy (0.9 event per 100 person-years; hazard ratio, 1.2; 95 percent confidence interval, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the two groups (hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.1). CONCLUSIONS: Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
In the citing paper
“However, it should be noted that patients considered to have a ' high risk of bleeding ' were excluded from the randomized trial described in the analysis above. 316”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“[7] Hazard ratios associated with low-intensity therapy as compared with conventional-intensity therapy (with 95 percent confidence intervals) and log-rank tests were used to compare the treatment groups.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079 · cited 1×
“Assays for factor V Leiden [4] and the G20210A mutation in the prothrombin gene [5] were performed in a central laboratory by technologists who were unaware of the patient's treatment-group assignment and clinical course.”
MethodOral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804 · cited 1×
“0 per 100 patient-years among those assigned to low-intensity therapy, [6] an average of 2.”
BackgroundSelf-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072 · cited 5×
“As in other studies, [2,10] factor V Leiden and prothrombin-gene mutations were not associated with a higher risk of recurrent thromboembolism, although all patients in our study were treated with anticoagulant therapy.”
BackgroundResultInfluentialSelf-citationNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 2×
“Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventional-intensity thera…”
BackgroundResultBeyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Research works printed but not linked: 3
- Kearon C, 2003, Circulation, 107, I
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Items 601–700 of 748
Venous thromboembolism in the elderly
Ploenes, C. (2016) · Phlebologie · doi:10.12687/phleb2315-4-2016 · Cited by 1
Anticoagulación extendida en la enfermedad tromboembólica venosa. A favor
Capitán, M. C. F. (2017) · Revista Clínica Española · doi:10.1016/j.rce.2017.02.017 · Cited by 1
Luizy, F. (2011) · Elsevier eBooks · doi:10.1016/b978-2-294-71346-0.50001-x · Cited by 1
Idiopathic Venous Thromboembolism
Sinescu, C. J. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4429-8_20 · Cited by 1
Anticoagulation for Venous Thromboembolism
Ortel, T. L. (2013) · Springer eBooks · doi:10.1007/978-3-319-01812-6_21 · Cited by 1
Managing Complications of Anticoagulant Therapy
Smythe, M. A., Dager, W. E., & Patel‐Shori, N. M. (2004) · Journal of Pharmacy Practice · doi:10.1177/0897190004271776 · Cited by 1
Recent advances in the diagnosis and treatment of pulmonary thromboembolism
Kucher, N., & Goldhaber, S. Z. (2003) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.09.066 · Cited by 1
Trombosi venosa: diagnosi e trattamento
Delsart, D., Girard, G., Moulin, N., Rivron-Guillot, K., & Decousus, H. (2008) · EMC - Urgenze · doi:10.1016/s1286-9341(08)70021-8 · Cited by 1
PREVENTION AND TREATMENT OF THROMBOEMBOLIC EVENTS IN MEDICAL PATIENTS AND NEW ANTICOAGULANTS
Balaratnam, S. (2009) · Acta Clinica Belgica · doi:10.1179/acb.2009.093 · Cited by 1
Depiction of residual emboli following pulmonary embolism with thrombotic scintigraphy
Takahashi, K., Ohnishi, M., Hiromoto, K., Ueda, A., Ohyanagi, M., & Naruse, H. (2005) · Annals of Nuclear Medicine · doi:10.1007/bf02985111 · Cited by 1
Seguimiento de la tromboembolia pulmonar
Uresandi, F., Iruín, G., Gómez, B., & Uresandi, A. (2008) · Medicina Clínica · doi:10.1016/s0025-7753(08)76450-9 · Cited by 2
Diagnosis and therapy in cancer-associated thromboembolism – what about guideline recommendations?
Matzdorff, A. C. (2015) · Phlebologie · doi:10.12687/phleb2288-6-2015 · Cited by 1
Diagnostik und Therapie der Rezidivthrombose
Blättler, W., & Gerlach, H.-E. (2006) · Gefässchirurgie · doi:10.1007/s00772-005-0443-y · Cited by 1
Progrès diagnostiques et thérapeutiques
Genest, M., & Pochmalicki, G. (2004) · La Presse Médicale · doi:10.1016/s0755-4982(04)98690-3 · Cited by 1
Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire
Tromeur, C., & Couturaud, F. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.07.005 · Cited by 1
Extended anticoagulation in venous thromboembolism disease. In favor
Fernández, M. C. (2017) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.04.003 · Cited by 1
Quel traitement anticoagulant au décours d’une embolie pulmonaire
Mao, R. L., Tromeur, C., & Couturaud, F. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.06.015 · Cited by 1
Anticoagulation for Proximal Deep Vein Thrombosis
Lee, A. I., & Lee, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-65226-9_23 · Cited by 1
Thomas, W., Symington, E. M., Besser, M. W., & Sheares, K. K. K. (2019) · British Journal of Haematology · doi:10.1111/bjh.15880 · Cited by 1
“The VTE recurrence rate reported here is comparable to two large historical trials using standard intensity warfarin, where recurrence rates of 0 7/100 patient years and 2 6/100 patient years, respectively, were reported (Kearon et al, 2003; Ridker et al, 2003).”
ResultLong-term outcome of pulmonary embolism
Meyer, G., Planquette, B., & Sanchez, O. (2008) · Therapy · doi:10.2217/14750708.5.2.159 · Cited by 1
Long term use of anticoagulant therapy for patients with pulmonary embolism
Becattini, C., & Cimini, L. A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1770589 · Cited by 1
“Two randomized studies were conducted with VKAs at subtherapeutic doses after the initial 3 to 6 months of conventional anticoagulation (Figure 1) [14,15].”
BackgroundBlättler, W., Amsler, F., Gerlach, H. E., Nüllen, H., Noppeney, T., Nüllen, C., Harenberg, J., Goecke, T. W., Beckmann, M. W., & Lawall, H. (2014) · Springer eBooks · doi:10.1007/978-3-642-21496-7_10 · Cited by 1
Goldhaber, S. Z. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_82 · Cited by 1
Yıldız, Z., Kayğın, M. A., Özkara, T., Limandal, H. K., Diler, M. S., Dayı, H. I. Ç., Ergün, S., & Dağ, Ö. (2023) · Vascular and Endovascular Surgery · doi:10.1177/15385744231184654 · Cited by 1
“It has been reported that recurrent DVT develops in approximately 2% to 25% of patients despite MT 18-21 .”
BackgroundDuration of anticoagulation of venous thromboembolism
Couturaud, F., Meneveau, N. F., Sevestre, M., Morange, P., & Jiménez, D. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104245 · Cited by 1
The Management of Venous Thromboembolic Disease
Obi, A. T., & Wakefield, T. W. (2018) · Advances in Surgery · doi:10.1016/j.yasu.2018.03.005 · Cited by 1
PREDICTORS OF MAJOR BLEEDING AMONG ATRIAL FIBRILLATION PATIENTS ON WARFARIN
Matalqah, L. M., Yehya, A., & Al‐Taani, G. M. (2019) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2019.v12i2.29955 · Cited by 1
Extension of anticoagulation after venous thromboembolism: Risk factors influencing the decision
Schulman, S. (2008) · Hämostaseologie · doi:10.1055/s-0037-1617168 · Cited by 1
Dumurgier, J., Desgranges, P., Chapoy, E., Becquemin, J.-P., & Hosseini, H. (2004) · Revue Neurologique · doi:10.1016/s0035-3787(04)71149-2 · Cited by 1
Reducing the risk of thromboembolic events
Huntington, S., & Acomb, C. (2008) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2008.3.6.31877 · Cited by 1
Maladie veineuse thrombo-embolique
Tromeur, C. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70341-5 · Cited by 1
Genetically Determined Procoagulant States and Heparin Use
McBane, R. D. (2003) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/108925320300700407 · Cited by 1
Granada, N., Eduardo, J., Garcia, P. S. C., Montoya, C. S., Luis, C., & Mier, G. (2014) · Cited by 1
ZAJAC, P. M. (2004) · Nursing Made Incredibly Easy! · doi:10.1097/00152258-200407000-00010 · Cited by 1
d -Dimer and Duration of Anticoagulation
Pernod, G., Sevestre, M., & Labarère, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmc063267 · Cited by 1
[Diagnosis and treatment of venous thrombosis].
Hach-Wunderle, V. (2005) · PubMed · Cited by 1
Kucher, N., & Goldhaber, S. Z. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0284-4.50060-9 · Cited by 1
Deep Vein Thrombosis and Pulmonary Embolism
Goldhaber, S. Z. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10015-x · Cited by 1
Tromboembolismo venoso en niños
Goldenberg, N. A., & Bernard, T. J. (2008) · Clínicas pediátricas de Norteamérica
Neue Aspekte zur Therapie der venösen Thromboembolie
Stümpflen, A. (2004) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Common clinical indications for anticoagulation
Krishnamoorthy, S., Khoo, C. W., Shantsila, E., & Lip, G. Y. H. (2010) · doi:10.1007/978-1-908517-08-1_2
Treatment of Deep Venous Thrombosis and Acute Pulmonary Embolism
Stein, P. D. (2007) · Wiley eBooks · doi:10.1002/9780470692042.ch87
Antiphospholipıd Syndrome and Venous Thrombosis
Okuyan, E. (2012) · InTech eBooks · doi:10.5772/27128
“Three prospective studies reported that there was an increased risk of recurrence that varied from 10% to 67% per year(Lim W 2006, Schulman S 1998, Kearon C 1999, Kearon C 2003, Ortel TL 2005).”
Estudo da trombose microvascular em biópsias pulmonares de pacientes com granulomatose de Wegener
Santana, A. N. C. (2008) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2008.tde-10102008-152122
Antithrombotic Therapy in Venous Thrombosis and Pulmonary Embolism
Nisio, M. D., & Buller, H. R. (2012) · Wiley eBooks · doi:10.1002/9781118410875.ch21
Behandlung bei akuter tiefer Beinvenenthrombose und Pulmonalembolie
Cr, C. (2014) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Therapy of Pulmonary Thromboembolism: an Evidence‐Based Approach
Riedel, M. (2005) · Wiley eBooks · doi:10.1002/9780470987377.ch40
Venous and arterial thrombosis : associations and risk factors
Roshani, S. (2012) · Leiden Repository (Leiden University)
Long-Term Management of Venous Thromboembolism: Strategies for Reducing the Risk of Recurrence
Piazza, G., Hohlfelder, B., & Goldhaber, S. Z. (2015) · Springer eBooks · doi:10.1007/978-3-319-20843-5_10
Differenzialdiagnose und Behandlung des akuten Kopfschmerzes
Rabe, K., & Kastrup, O. (2012) · Notfall + Rettungsmedizin · doi:10.1007/s10049-012-1653-y
“Neu aufgetretene chronische Kopfschmerzen in der Schwangerschaft, bei Koagulopathie und Östrogentherapie soll ten beim Untersucher den Verdacht auf eine SVT wecken.”
BackgroundInfluentialChronic thromboembolic pulmonary hypertension; how does it develop and how can it be recognised?
Lewczuk, J. (2006) · Cardiology Journal
Zasady leczenia wstępnego i wtórnej profilaktyki przeciwzakrzepowej w zatorze tętnicy płucnej
Kostrubiec, M., & Pruszczyk, P. (2010) · Via Medica Journals
Gerinnungsselbstmanagement der oralen Antikoagulation
Bernardo, A. (2010) · Springer eBooks · doi:10.1007/978-3-642-01544-1_48
Conventional Treatment of Deep Venous Thrombosis
Pineo, G. F., & Hull, R. D. (2007) · Elsevier eBooks · doi:10.1016/b978-012369515-4/50046-6 · Cited by 1
Quel suivi proposer après la première embolie pulmonaire ?
Leroyer, C., Pigearias, B., & Sanchez, O. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72485-1
Fibrinolysis – new perspectives Fibrinolysis-neue Perspektiven
Schambeck, C. M. (2005) · Journal of Laboratory Medicine · doi:10.1515/jlm.2005.053
Ximelagatran for Treatment and Prophylaxis of Recurrent Events in Deep Vein Thrombosis
Koscielny, J., Kiesewetter, H., Jörg, I., & Harenberg, J. (2007) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029607302561
Pulmonary Embolism in Orthopaedic Patients: Diagnosis and Treatment
Elias, D. J. (2004) · Techniques in Orthopaedics · doi:10.1097/01.bto.0000145151.79939.fe
Bleeding risk assessment during oral anticoagulant therapy initiation
Lazo‐Langner, A., Kovacs, M. J., & Louzada, M. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.10
Self-citationWittkowsky, A. K. (2004) · Journal of Pharmacy Practice · doi:10.1177/0897190004272571
“Those questions were answered in the subsequent ELATE trial, which enrolled 738 patients with a history of idiopathic VTE who had completed at least 3 months of standard anticoagulation.(35) Patients were randomized to anticoagulation with continued moderateintensity therapy or to low-intensity warfarin and continued…”
BackgroundLes anticoagulants nouveaux sont arrivés
Sztrymf, B., & Humbert, M. J. C. (2004) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(04)71350-9
Ansell, J. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-5575-8
“Two recent studies, the PREVENT trial [1] and the ELATE trial [2] tested two different intensities of therapy and arrived at compatible results but differing recommendations, thus leading to a controversy as to what is the appropriate therapy.”
ResultLe traitement anticoagulant de l’embolie pulmonaire. Quelle durée ?
Tromeur, C., Leroyer, C., & Couturaud, F. (2012) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(12)70314-0
Changing Paradigms in the Management of Venous Thromboembolism
Weitz, J. I. (2006) · The American Heart Hospital Journal · doi:10.1111/j.1541-9215.2006.04650.x
Self-citationRécidive : Quel bilan ? Quel traitement ? Quel suivi ?
Leroyer, C., Pigearias, B., & Couturaud, F. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72486-3
Duration of Treatment of Deep Vein Thrombosis: Time for a New Approach?
Rychlik, P. G., Henry, K. S., & Bussey, H. I. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.8.1112
Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement
Prandoni, P. (2004) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.9.4.106
Telitromicina, un posible nuevo potenciador del acenocumarol
García-Fuster, M. J., Domínguez, E., Martínez, F., & Forner, M. J. (2006) · Medicina Clínica · doi:10.1157/13089107
Widimsky, J., Jr., Maly, J., Franc, P., Kautzner, J., & Praha, I. (2007)
Tiefe Venenthrombose bei junger Frau mit heterozygoter Faktor-V-Leiden-Mutation
Zotz, R. B., Gerhardt, A., & Sucker, C. (2010) · Gefässchirurgie · doi:10.1007/s00772-010-0796-8
Ximelagatran prevented secondary venous thromboembolism
Prandoni, P. (2004) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.9.4.107
Conduite à tenir devant une douleur thoracique
Couturaud, F. (2007) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(07)91582-x
Current issues facing coagulationists – meeting report1
Brown, S. A., Aledort, L. M., & Lee, C. A. (2006) · Haemophilia · doi:10.1111/j.1365-2516.2006.01169.x
Why not test for hypercoagulability in patients with idiopathic venous thromboembolism?
Brotman, D. J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.09.003
Duration of Anticoagulant Treatment after VenousThromboembolism
Becattini, C., & Agnelli, G. (2003) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000083828
Gumulec, J., Kessler, P., Penka, M., Klodová, D., Králová, S., Brejcha, M., Wróbel, M., Blatný, J., Klaricová, K., & Lasota, Z. (2006)
Budd-Chiari Syndrome: New insights in Pathogenesis, Management and Prognosis
Murad, S. D. (2004)
Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease
Dittus, C. E., & Ansell, J. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4297-3_5
Methods to Predict Individualized Combined Benefit/Harm Patient Profiles for Warfarin
Pereira, J. A. (2009) · TSpace (University of Toronto) · Cited by 2
Low-Intensity Warfarin Is Too Low
Krumholz, H. M., & Sm (2004) · Journal watch · doi:10.1056/jc200401020000009
Current and emerging treatment options for venous thrombosis: A case discussion
Haines, S. T., & Nutescu, E. A. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.6.593
Differenzialdiagnose und Behandlung des akuten Kopfschmerzes
Rabe, K., & Kastrup, O. (2013) · CME · doi:10.1007/s11298-013-0140-1
Point of care testing for PT-INR
Madoiwa, S. (2012) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.23.580
Starting insulin therapy (August 2015)
Weiß, D. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82c.10001
Anticoagulation Drugs: Indications, Therapeutic Monitoring, and Antidotes
Sharda, A. V., & Zwicker, J. I. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_44
Goldhaber, S. Z., Weitz, J. I., & Piazza, G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2930-6.00053-7
Self-citationFitzgerald, K. C., & Glynn, R. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384978-6.00067-4
Conventional vs. Low-Intensity Warfarin to Prevent Recurrent VTE
Brett, A. S. (2003) · Journal watch · doi:10.1056/jw200308260000001
Monitoring and Reversal of Oral Anticoagulation in Hospitalized Patients
Chatalbash, A., & Morgenstein, C. (2017) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2017.04.004
Overview of Anticoagulation Agents
Jorshery, S. D., Aurshina, A., & Chaar, C. I. O. (2017) · Springer eBooks · doi:10.1007/978-3-319-65226-9_21
Anticoagulation in Venous Thromboembolism
Barnes, G. D., & Renner, E. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_14
Braga, G. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2017.tde-27072016-154027
Cho, J. H., & Kim, Y. (2018) · Clinical & Experimental Thrombosis and Hemostasis · doi:10.14345/ceth.18001
“0)을 비교하였다.(46) 저 강도 와파린 치 료는 VTE 재발의 위험도를 증가시켰고(HR 2.”
EINSTEIN-CHOICE trial – rationale for the extended anticoagulation in secondary prevention
Tamburrini, L. R., Weißer, G., & Espinola–Klein, C. (2018) · VASA · doi:10.1024/0301-1526/a000707
“First, vitamin K antagonists have been tested in a reduced dosage [5].”
BackgroundEXTENDED ANTICOAGULANT THERAPYIN PATIENTS, WHO SURVIVED PULMONARY EMBOLISM
Vorobieva, N. M., & Панченко, Е. П. (2018) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2018-2-36-45
Warfarin and other vitamin K antagonists
Stein, P. D. (2016) · Wiley eBooks · doi:10.1002/9781119039112.ch104
Валерьевич, А. О., Vechorko, V. I., & Shapsigova, O. A. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-21-8-15
Instituto de Investigaciones Clínicas “Dr. Américo Negrette”, F. D. M., Vizcaíno, G., Instituto de Investigación. Universidad Técnica Manabí, P. E., Medina, J. W., Instituto Hematológico de Occidente, M., Quintero, J., Instituto de Investigaciones Clínicas “Dr. Américo Negrette”, F. D. M., Vizcaíno-Carruyo, J., & Editorial Médica Colombiana, M. (2020) · Investigación Clínica · doi:10.22209/ic.v61n1a07
Amruthlal, M., Devika, S. V., A, A. S. P., Menon, A. K., Krishnan, V., Thomas, A., Thomas, M., Sanjay, G., R, L. K. L., Jose, J., et al. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2004.11460
“Identifying a stable dose of warfarin just after initiation of the drug is a tedious process which requires supervision of a physician and is usually done before the patient is discharged, for example after the valve surgery [1].”
Background
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., & Gent, M.
- Affiliations
- McMaster University (CA)
- Western University (CA)
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of New Brunswick (CA)
- University of Toronto (CA)
- McGill University (CA)
- Université Laval (CA)
- Université de Montréal (CA)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 631-639
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009013630
- Cited by
- 751
- References
- 12
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 17 · 2019: 25 · 2018: 38 · 2017: 26 · 2016: 29 · 2015: 27 · 2014: 31 · 2013: 58 · 2012: 45
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, low-intensity anticoagulation, venous thromboembolism, recurrent venous thromboembolism, unprovoked venous thromboembolism, international normalized ratio, bleeding risk, anticoagulation intensity, long-term prophylaxis
- MeSH terms
- Age Factors, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk Factors, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.